Amylin Pharma (AMLN) Added To Goldman Sachs Conviction Buy List; Gilead (GILD) Removed
More News related to AMLN
- Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: LPX, SHPGY, WNR, WIN, AMLN, STEC
- Canaccord Adams Upgrades Amylin Pharmaceuticals (AMLN) to Hold; Competitors on the Way and Safety Issues May Continue to Weigh on Shares
- Notable Analyst Rating Changes 10/06: MON, DLTR, AMLN, JBL Upgraded; KO, CLS, RFMD, MT Downgraded
- Citi Upgrades Amylin Pharmaceuticals (AMLN) to Hold
- Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
More News related to GILD
- Gilead Sciences to Release Third Quarter 2008 Financial Results on Thursday, October 16, 2008
- Notable Analyst Rating Changes 10/3: COST, CS, CSX, URBN Upgraded; CMI, WAG, SGP, SCG Downgraded
- Merrill Lynch Resumes Coverage on Gilead Sciences (GILD)
- Citi Maintains a 'Buy' on Gilead Sciences (GILD), Saying Stock is Oversold
- David Moenning's Daily State of the Markets: 9/24
More News related to Analyst Comments
- AmTech Reiterates Sell on Amazon (AMZN); Cuts PT to $45
- Canaccord Adams Maintains 'Buy' Rating on VALE (RIO), but Lowers Price Target
- Canaccord Adams Maintains 'Buy' Rating on Thompson Creek Metals (TC)
- Canaccord Adams Maintains 'Buy' Rating on Taseko Mines Limited (TGB)
- Analyst Starts Coverage on Solar Sector with an Underperform; Sees Stocks Falling At Least Another 30-40%
Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) has been added to Goldman Sachs Conviction Buy List.
Gilead Sciences Inc. (Nasdaq: GILD) has been removed from Goldman Sachs Conviction Buy List.
Related Categories
Analyst CommentsStocks Mentioned
-1.38Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
